Avalo Therapeutics, Inc.
AVTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $192 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $87 |
| Gross Profit | $0 | $0 | $0 | $105 |
| % Margin | – | – | – | 54.7% |
| R&D Expenses | $13,621 | $14,074 | $9,123 | $8,183 |
| G&A Expenses | $5,555 | $5,186 | $5,534 | $4,444 |
| SG&A Expenses | $5,577 | $5,242 | $5,546 | $5,233 |
| Sales & Mktg Exp. | $22 | $56 | $12 | $789 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19,198 | $19,316 | $14,669 | $13,416 |
| Operating Income | -$19,198 | -$19,316 | -$14,669 | -$13,311 |
| % Margin | – | – | – | -6,932.8% |
| Other Income/Exp. Net | -$11,416 | -$1,433 | $1,528 | -$21,914 |
| Pre-Tax Income | -$30,614 | -$20,749 | -$13,141 | -$35,225 |
| Tax Expense | $11 | $16 | $8 | $114 |
| Net Income | -$30,625 | -$20,765 | -$13,149 | -$35,339 |
| % Margin | – | – | – | -18,405.7% |
| EPS | -2.19 | -1.92 | -1.25 | 13.89 |
| % Growth | -14.1% | -53.6% | -109% | – |
| EPS Diluted | -2.19 | -1.92 | -1.25 | 10.47 |
| Weighted Avg Shares Out | 14,000 | 10,830 | 10,515 | 10,472 |
| Weighted Avg Shares Out Dil | 14,000 | 10,830 | 10,515 | 10,472 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,117 | $1,102 | $1,148 | $1,216 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $59 | $134 | $135 | $68 |
| EBITDA | -$30,555 | -$19,182 | -$14,534 | -$13,243 |
| % Margin | – | – | – | -6,897.4% |